We are pleased to announce that KYBORA is moving to a new office location on Witherspoon Street in Princeton, New Jersey.  The new office is ideally located within walking distance of downtown Princeton, the university, and biotech incubator groups, and provides easy access to all major biopharma companies located in New Jersey and Pennsylvania. Our new […]

Read more

BASEL, SWITZERLAND (PRWEB) MARCH 17, 2021 Alan Vanderborght, founder and Chief Executive Officer of KYBORA Group and Chairman of the Board of Directors of KYBORA GmbH, said, “I am thrilled to have Sascha, Eric, and Stephen join our team. Their experience in launching companies, running operations, and the extent of their networks will be of great […]

Read more

PRINCETON, N.J., AND BASEL, SWITZERLAND (PRWEB) MARCH 17, 2021 Alan Vanderborght said, “I am thrilled to have Jean join our team. He brings more than two decades of diversified corporate and business development experience in the pharmaceutical and biotechnology sectors, spanning a broad range of therapeutic areas, asset (biopharma product as well as technology platforms) stages, […]

Read more

PRINCETON, N.J. (PRWEB) MARCH 16, 2021 Alan Vanderborght, Founder and CEO of KYBORA, said: “The opening of KYBORA GmbH is the next phase in KYBORA’s growth. With its inception, we aim to provide high quality M&A, licensing, fundraising, and strategic consulting services to the European pharma and biotech industry. Basel is the ideal location for our […]

Read more

KYBORA is an experienced global advisory firm that maintains close direct connections with the top 20 market leaders through regular updates and networking

Read more

KYBORA is happy to announce that it will sponsor the Bio Latin America Conference again this year. Taking place in Sao Paulo on September 3rd and 4th 2019, Bio Latin America is a must attend event that gathers many of the key players in the pharma and biotech industry in Latin America. KYBORA looks forward to meeting […]

Read more

“If you are a U.S. company that does not yet have a China strategy…you need to get moving or risk missing out on a potentially big market,” Brad Loncar, CEO of Loncar Investments, wrote after attending this year’s China Healthcare Investment Conference. Trip reports like these are rolling in, reaffirming what is becoming more and […]

Read more

KYBORA is pleased to announce that it has successfully helped its client STADA Arzneimittel AG license Xlucane – a Ranibizumab (Lucentis) biosimilar to Bausch Health. This latest transaction reinforces KYBORA’s capability in delivering complex cross border transactions working with leading global pharmaceutical companies. “We are seeing an increase in the number of biosimilar deals around […]

Read more

KYBORA is pleased to announce that Anton Leshchenko has joined its team as Managing Director, responsible for expanding KYBORA’s operations in Russia, CIS/CEE, and Africa.  Anton is a senior executive with 18+ years of life science and medical disposables experience with turn around and value addition achievements in territory management and BD&L (both in-/ out-license, […]

Read more

KYBORA Welcomes Rainer Wulf to the Team

KYBORA is pleased to announce that Rainer Wulf has joined Kybora as a new member of the advisory board. Rainer is a Senior Executive with 30+ years of experience in the pharmaceutical industry, most of them in international positions, starting in sales and followed by Restructuring/Optimization of Sales Organizations, leadership positions in Marketing up to […]

Read more

TYPE & ENTER: